, , , , , *
(1.Department of Radiology, Shengjing Hospital of China Medical University,Shenyang 110004, China; 2.Department of Interventional Radiology,Dalian Municipal Women and Children,s Medical Center,Dalian 116037, China)
?
"Kissing stent" reconstruction in treatment of complex and long-segment aortoiliac occlusive disease
ZHENGJiahe1,CHANGZhihui1,WANGChuanzhuo1,WANGYitang2,LIUZhaoyu1,GUOQiyong1*
(1.DepartmentofRadiology,ShengjingHospitalofChinaMedicalUniversity,Shenyang110004,China; 2.DepartmentofInterventionalRadiology,DalianMunicipalWomenandChildren,sMedicalCenter,Dalian116037,China)
Objective To evaluate the feasibility and effectiveness of "kissing stent" reconstruction (KSR) in patients with complex and long-segment aortoiliac occlusive disease (AIOD). Methods A total of 20 patients with complex and long-segment AIOD were enrolled in the study. The planned treatment mainly included two steps. Firstly, antegrade recanalization was performed from brachial artery access. Secondly, angioplasty with KSR was performed in distal aorta and bilateral iliac arteries. Intraoperative and postoperative complications, postoperative ankle-brachial index (ABI) and Rutherford classification were recorded. Patency rate was observed at 6, 12 and 24 months after treatment. Results KSR was successfully performed on 18 patients. Recanalization of only one iliac artery was achieved for another 2 patients. Popliteal artery embolization occurred in 1 case, who was recoveryed after anticoagulation and thrombolysis therapy. During the operation, iliac artery dissection occurred in 2 cases. And the dissection disappeared after placing stents. Hematoma in the access site occurred in 3 patients and was absorbed after symptomatic treatment. There were statistical differences of Rutherford classification and both left and right ABI between the measurement of preoperative and 1 month after treatment (allP<0.05). In-stent restenosis of iliac artery occurred in 1 case at 6 month and occlusions in 2 cases at 12 and 24 month after treatment, respectively. For above 3 patients, target lesion revascularization was performed successfully. A patient died of myocardial infarction at 17 months postoperatively. The primary patency rate was (94.44±5.40)%, (88.89±7.40)% and (81.50±9.80)% at 6, 12 and 24 months after treatment, respectively. Conclusion KSR is feasible for patients with long-segment and complex AIOD, which has excellent short-term and mid-term effect and low complication rates.
Stents; Aortoiliac occlusion; Endovascular therapy
腔內(nèi)治療是限局性(TASC A、B級)主髂動脈閉塞(aortoiliac occlusive disease, AIOD)的主要治療手段[1-3]。近年來,隨著介入技術的提高及新器材的研發(fā),復雜病變的腔內(nèi)治療成功率也隨之增高。目前臨床對TASC A、B、C級病變首選腔內(nèi)治療,而對TASC D級病變,尤其是復雜長段AIOD的開通腔內(nèi)治療仍較為困難。對吻式支架主要用于TASC A、B級AIOD的腔內(nèi)治療,而在TASC D級AIOD的應用鮮見報道[4-8]。本研究探討采用對吻式支架治療復雜長段(大于10 cm)AIOD的可行性及療效。
1.1一般資料 2009年6月—2014年6月于我院接受腔內(nèi)治療的復雜長段AIOD患者20例,其中男15例,女5例,年齡38~76歲,中位年齡62歲,病程8~40個月,中位病程22個月。術前均經(jīng)CTA證實為復雜長段AIOD;5例腹主動脈閉塞近端距腎動脈開口<2 cm(圖1A);閉塞遠端位于髂總動脈4例,位于髂外動脈16例;腹主動脈閉塞長度5.87~10.43 cm,中位數(shù)7.18 cm;右髂動脈閉塞長度4.54~11.78 cm,中位數(shù)8.42 cm;左髂動脈閉塞長度3.42~12.23 cm,中位數(shù)10.17 cm。4例同時合并股淺動脈閉塞。20例患者術前左、右側踝肱指數(shù)(ankle-brachial index, ABI)分別為0.24~0.46和0.22~0.41,中位數(shù)分別為0.38和0.34;Rutherford分級為2級2例,3級7例,4級6例,5級5例。12例伴高血壓,10例伴糖尿病,9例伴高脂血癥,7例伴冠心病,5例伴腦梗死。
1.2治療方法
1.2.1術前準備 囑患者術前至少3天開始口服拜阿司匹林(每天100 mg)和氯吡格雷(每天75 mg);或于手術當日口服負荷劑量拜阿司匹林和氯吡格雷,各300 mg。
1.2.2腔內(nèi)治療 采用Siemens Artis DSA系統(tǒng)作為影像引導設備。首先經(jīng)左側肱動脈入路,以5F豬尾導管行腹主動脈及雙下肢動脈造影。進行造影評估(圖1B、1C)后,將6F長鞘交換至閉塞段上方,再沿鞘送入5F多功能導管,以加硬導絲開通閉塞段腹主動脈及一側髂動脈。經(jīng)造影證實后,于透視下以導絲為引導,穿刺同側股動脈,并置入6F動脈鞘。將導絲通過“穿線”技術或抓捕器經(jīng)動脈鞘引出,并更換導絲方向。若導絲進入髂動脈內(nèi)膜下無法返回真腔,則采用路圖引導穿刺同側股動脈,行雙向內(nèi)膜下開通閉塞段。并以同法開通另一側閉塞血管。
如成功開通雙側閉塞血管,則首先采用4~120 mm球囊導管由腹主動脈閉塞段開始進行對吻式預擴張,擴張前以造影測量閉塞段近端與腎動脈的距離,對距離<2 cm者經(jīng)肱動脈途徑置入PT2導絲進行預防性保護。而后,同時經(jīng)雙側股動脈入路于腹主動脈下段及雙側髂動脈內(nèi)對吻式置入血管內(nèi)支架,支架長度充分跨越病變段,再以球囊行對吻式后擴張。
術中對所有患者均給予5 000 U肝素鈉行全身肝素化,如手術時間>1 h,則追加1 000 U肝素鈉。手術成功標準為腔內(nèi)治療后即刻造影顯示血管腔通暢(圖1D、1E),殘余狹窄<30%。
1.3療效評價及隨訪 于腔內(nèi)治療術后1個月復查ABI并評估Rutherford分級情況,術后6、12個月常規(guī)門診復查,以后每年復查1次,如癥狀復發(fā)則隨時進行檢查。隨訪內(nèi)容主要包括:癥狀、體征和ABI,評估術后6、12和24個月的一期通暢率(以每例患者為單位)。當臨床疑似支架內(nèi)再狹窄或閉塞時行CTA檢查(圖1F),管腔狹窄>50%定義為再狹窄。
1.4統(tǒng)計學分析 采用SPSS 16.0統(tǒng)計分析軟件。術前與術后ABI和Rutherford分級的比較采用非參數(shù)Wilcoxon秧檢驗,應用Kaplan-Meier法分析支架通常率。P<0.05為差異有統(tǒng)計學意義。
對18例成功置入對吻式支架,共置入69個支架,均為自膨式裸支架,其中置入2枚支架2例,3枚支架3例,4枚支架10例,5枚支架2例,6枚支架1例。另2例患者腹主動脈閉塞位于腎動脈水平,對其僅行單側開通。
圖1 患者男,59歲 A.術前CTA示腹主動脈下段及雙側髂動脈閉塞,血管壁鈣化; B、C.腔內(nèi)治療術中血管造影示腎動脈以下腹主動脈及雙側髂總、髂外動脈閉塞; D、E.腔內(nèi)治療術后血管造影示主髂血流恢復通暢; F.腔內(nèi)治療術后12個月復查CTA示主髂動脈支架通暢
18例置入對吻式支架的患者中,對16例一次性開通腹主動脈及雙側髂動脈,直接行對吻式支架置入術;另2例首次僅開通腹主動脈及一側髂動脈,于腹主動脈及開通側髂動脈內(nèi)留置溶栓導管,每24 h給與尿激酶60萬U(分兩次經(jīng)導管于2 h內(nèi)泵入),48 h后再次手術均成功開通對側髂動脈,而后行對吻式支架置入。
術中對2例患者在腎動脈留置保護性導絲,術后造影腎動脈均未發(fā)現(xiàn)異常。術中1例患者斑塊脫落,導致腘動脈栓塞,給予尿激酶50萬U溶栓及抗凝治療后好轉。對2例患者開通髂動脈時發(fā)生小動脈夾層,置入支架后夾層消失。術后1例肱動脈穿刺處血腫,2例股動脈穿刺處血腫,經(jīng)對癥治療后血腫均自行吸收。
患者術后1個月左、右側ABI分別為為0.79~0.98和為0.81~1.01,中位數(shù)分別為0.87和0.88,與術前(0.38和0.34)比較差異均有統(tǒng)計學意義(P均<0.05)。術后Rutherford分級為0級5例,1級8例,2級6例,3級1例;與術前(2級2例,3級7例,4級6例,5級5例)分級差異有統(tǒng)計學意義(P<0.05)。
術后隨訪13~41個月,中位隨訪時間27個月。1例于術后6個月支架再狹窄,1例于術后12個月、1例子于24個月支架閉塞,對此3例患者均成功進行靶血管再通。1例患者術后17個月死于心肌梗死。術后6、12和24個月一期通暢率分別為(94.44±5.40)%、(88.89±7.40)%和(81.50±9.80)%。
腹主-雙髂(股)動脈人工血管旁路移植術曾被認為是復雜長段AIOD的首選治療方法。但由于多數(shù)患者年齡較高,機體一般情況較差,且外科手術的創(chuàng)傷大,圍手術期死亡率和術后并發(fā)癥發(fā)生率高等原因,限制了外科手術的應用。介入腔內(nèi)治療具有創(chuàng)傷小、方法多樣、安全有效等特點,已廣泛用于AIOD的治療,且對多數(shù)主髂動脈閉塞患者均可首選腔內(nèi)治療[9]。
介入治療的目的是恢復主髂動脈血流,由于復雜長段AIOD幾乎均于腹主動脈杈存在嚴重的非血栓性狹窄或閉塞,如僅對一側髂動脈行球囊成形及支架置入,則易造成血管成角及對側血流遮擋等問題,故臨床多主張行對吻式球囊成形及支架置入術[6]。由于主髂動脈閉塞段較長,經(jīng)股動脈逆行開通導絲易進入內(nèi)膜下,而導絲一旦進入腹主動脈內(nèi)膜下則難以返回真腔,故本研究采用經(jīng)肱動脈順行開通方法。本組中,對2例首次僅開通單側髂動脈,導絲無法進入另一側髂動脈,溶栓后對側髂動脈開口顯影并順利開通,提示溶栓治療可在腔內(nèi)治療血管開通困難時作為輔助手段。
Dosluoglu等[10]認為當腹主動脈閉塞水平接近腎動脈開口時,進行介入治療有腎動脈甚至腸系膜上動脈栓塞的風險,推薦進行外科手術治療。Yuan等[8]對5例復雜長段AIOD患者聯(lián)合應用導管直接溶栓(catheter-directed thrombolysis, CDT)治療,結果顯示其中4例治療效果滿意。閉塞段接近腎動脈開口水平,開通過程中導絲易通過閉塞段是溶栓的適應證[8-11]。Krankenberg等[7]認為當腹主動脈閉塞近端與腎動脈距離<2 cm時,可進行必要的預防性保護,以及時處理腎動脈血管栓塞等并發(fā)癥。
本組患者術后ABI值和Rutherford分級與術前比較差異均有統(tǒng)計學意義(P均<0.05);中位隨訪時間為27個月,術后6、12和24個月的一期通暢率分別為(94.44±5.40)%、(88.89±7.40)%和(81.50±9.80)%,與既往研究[12-13]結果相似。腔內(nèi)治療患者創(chuàng)傷小、恢復快,易于接受再次治療。本組3例術后支架再狹窄或閉塞的患者經(jīng)再次治療后靶血管均成功再通。本組4例同時合并股淺動脈閉塞的患者,由于股深動脈代償良好,術后均未進行特殊處理。
Krankenberg等[7]認為,當腹主動脈閉塞段長度超過3 cm時,應先留置腹主動脈支架,而后在其末端對吻式置入髂動脈支架。直接采用對吻式支架操作簡單、快速,有助于減少并發(fā)癥;應用腹主動脈支架操作相對復雜,并發(fā)癥出現(xiàn)的概率可能更高,且需交換粗動脈鞘,增加了止血的難度,易造成穿刺點出血等并發(fā)癥;本研究未根據(jù)主動脈閉塞長度選擇腹主動脈支架,均采用對吻式方法置入支架。術后常見的輕微并發(fā)癥主要是穿刺點血腫,本組術后1例肱動脈穿刺處血腫及2例股動脈穿刺處血腫患者經(jīng)對癥治療后均好轉。術中采用縫合器有助于減少術后穿刺處血腫的發(fā)生;此外,導絲開通髂動脈過程中易進入內(nèi)膜下,從而出現(xiàn)小的夾層,應仔細操作以避免血管破裂。
總之,經(jīng)肱動脈順行開通復雜長段AIOD具有較高的成功率,且并發(fā)癥發(fā)生率較低,可作為開通主髂動脈閉塞的首選方法;對吻式支架置入后,近、中期通暢率高,長期療效還有待于進一步隨訪研究。
[1] Sharafuddin MJ, Hoballah JJ, Kresowik TF, et al. Kissing stent reconstruction of the aortoiliac bifurcation. Perspect Vasc Surg Endovasc Ther, 2008,20(1):50-60.
[2] Picquet J, Blin V, Bouyé P, et al. Endovascular treatment for obstructive disease of the aortoiliac bifurcation by the kissing stent technique. J Mal Vasc, 2005,30(3):163-170.
[3] Sabri SS, Choudhri A, Orgera G, et al. Outcomes of covered kissing stent placement compared with bare metal stent placement in the treatment of atherosclerotic occlusive disease at the aortic bifurcation. J Vasc Interv Radiol, 2010,21(7):995-1003.
[4] Suzuki K, Mizutani Y, Soga Y, et al. Efficacy and Safety of Endovascular Therapy for Aortoiliac TASC D Lesions. Angiology, 2016, Mar 15. [Epub ahead of print].
[5] Schmalstieg J, Zeller T, Tübler T, et al. Long term data of endovascularly treated patients with severe and complex aortoiliac occlusive disease. J Cardiovasc Surg (Torino), 2012,53(3):291-300.
[6] Setacci C, Galzerano G, Setacci F, et al. Endovascular approach to Leriche syndrome. J Cardiovasc Surg (Torino), 2012,53(3):301-306.
[7] Krankenberg H, Schlüter M, Schwencke C, et al. Endovascular reconstruction of the aortic bifurcation in patients with Leriche syndrome. Clin Res Cardiol, 2009,98(10):657-664.
[8] Yuan L, Bao J, Zhao Z, et al. Endovascular therapy for long-segment atherosclerotic aortoiliac occlusion. J Vasc Surg, 2014,59(3):663-668.
[9] 陳忠,寇鐳.復雜主髂動脈閉塞癥的治療選擇.外科理論與實踐,2015,20(4):289-293.
[10] Dosluoglu HH. Commentary: endovascular therapy should be the first line of treatment in patients with severe (TASC Ⅱ C or D) aortoiliac occlusive disease. J Endovasc Ther, 2013,20(1):74-79.
[11] Moise MA, Alvarez-Tostado JA, Clair DG, et al. Endovascular management of chronic infrarenal aortic occlusion. J Endovasc Ther, 2009,16(1):84-92.
[12] van't Riet M, Spronk S, Jonkman J, et al. Endovascular treatment of atherosclerosis at the aortoiliac bifurcation with kissing stents or distal aortic stents: A temporary solution or durable improvement? J Vasc Nurs, 2008,26(3):82-85.
[13] Greiner A, Dessl A, Klein-Weigel P, et al. Kissing stents for treatment of complex aortoiliac disease. Eur J Vasc Endovasc Surg, 2003,26(2):161-165.
鄭加賀(1974—),男,遼寧海城人,博士,副教授。研究方向:外周血管疾病介入治療。E-mail: zhengjh@sj-hospital.org
郭啟勇,中國醫(yī)科大學附屬盛京醫(yī)院放射科,110004。E-mail: qiyongguo123@126.com
2016-07-01
2016-09-12
對吻式支架治療復雜長段主髂動脈閉塞
鄭加賀1,暢智慧1,王傳卓1,王毅堂2,劉兆玉1,郭啟勇1*
(1.中國醫(yī)科大學附屬盛京醫(yī)院放射科,遼寧 沈陽 110004;2.大連婦女兒童醫(yī)療中心放射介入科,遼寧 大連 116037)
目的 評價對吻式支架治療復雜長段主髂動脈閉塞(AIOD)的可行性及療效。方法 對20例復雜長段主髂動脈閉塞患者,擬采用經(jīng)肱動脈途徑順行開通閉塞段血管后,于腹主動脈下段及雙側髂動脈置入對吻式支架進行治療。記錄術中及術后并發(fā)癥情況、術后踝肱指數(shù)(ABI)及Rutherford分級。隨訪觀察術后6、12、24個月支架通暢率。結果 20例中,對18例成功置入對吻式支架,對另2例僅行腹主動脈及單側髂動脈開通。術中1例斑塊脫落導致腘動脈栓塞的患者,經(jīng)溶栓及抗凝治療后好轉。術中開通髂動脈時,2例發(fā)生小動脈夾層,置入支架后夾層消失。術后3例穿刺處血腫的患者經(jīng)對癥治療后血腫均自行吸收。術后1個月患者左、右側ABI及Rutherford分級均與術前差異有統(tǒng)計學意義 (P均<0.05)。1例術后6個月發(fā)生支架再狹窄、2例分別術后12個月和24個月發(fā)生支架閉塞,對其均成功進行靶血管再通。1例患者術后17個月死于心肌梗死。術后6、12和24個月一期通暢率分別為(94.44±5.40)%、(88.89±7.40)%和(81.50±9.80)%。結論 以對吻式支架治療復雜長段主髂動脈閉塞近、中期療效較好,且并發(fā)癥相對較少。
支架;主髂動脈閉塞;腔內(nèi)治療
R654.3; R816
A
1672-8475(2016)10-0592-04
10.13929/j.1672-8475.2016.10.003